{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:31:39Z","timestamp":1793608299004,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is an understudied, life-threatening genetic disorder affecting \u223c300 000 infants yearly with limited treatment options. The complement system, a critical part of innate immunity, has emerged as a contributor to SCD pathophysiology, thus presenting a potential new treatment target. Our aim was to assess complement activity in children with SCD receiving hydroxyurea (HU) therapy during vaso-occlusive crisis (VOC) and steady state. Blood samples were collected from 46 pediatric patients with SCD during VOC (early and late) and steady state, with control samples from healthy volunteers. Clinical data were obtained from patient records, and patient heme levels were measured using colorimetric assay. Complement deposition on endothelial cells (ECs) was quantified using high-throughput automated immunofluorescence imaging. Complement protein concentration was measured using enzyme-linked immunosorbent assay and multiplex assays. We found that, in vitro, heme drove C3b and C5b-9 deposition on ECs. Patients had increased heme levels during both VOC and steady state compared with healthy controls. However, complement activation correlated with total hemoglobin (Hb) concentration in patients during steady state, but not heme levels. C5b-9 deposition on ECs was significantly higher in patients during early crisis compared with late crisis, suggesting heightened complement activity early in VOC, with C5b-9 deposition also strongly correlating with circulating soluble C5b-9 levels. A significant increase in the C3b\/C3 ratio further indicated early complement activation during VOC. In conclusion, complement activity is likely highest in early VOC in patients with SCD, and presents a critical potential treatment target, but is overall attenuated by HU therapy despite elevated heme or Hb levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016958","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T21:04:26Z","timestamp":1763586266000},"page":"1168-1178","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of complement activation in a hydroxyurea-treated patient cohort with sickle cell disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-5587","authenticated-orcid":false,"given":"Daniel","family":"Diatlov","sequence":"first","affiliation":[{"name":"1Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Cell & Systems Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4435-9336","authenticated-orcid":false,"given":"Arlette","family":"Bohorquez-Hernandez","sequence":"additional","affiliation":[{"name":"2Cell & Systems Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-8538","authenticated-orcid":false,"given":"Melanie","family":"Kirby-Allen","sequence":"additional","affiliation":[{"name":"3Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[{"name":"1Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada"},{"name":"2Cell & Systems Biology, The Hospital for Sick Children Research Institute, Toronto, ON, Canada"},{"name":"4Division of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"9757","key":"2026022411371695300_bib1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"2026022411371695300_bib2","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026022411371695300_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.tracli.2019.02.008","article-title":"Complement activation during intravascular hemolysis: implication for sickle cell disease and hemolytic transfusion reactions","volume":"26","author":"Merle","year":"2019","journal-title":"Transfus Clin Biol"},{"issue":"5","key":"2026022411371695300_bib4","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy","volume":"95","author":"Roumenina","year":"2020","journal-title":"Am J Hematol"},{"issue":"807","key":"2026022411371695300_bib5","doi-asserted-by":"crossref","first-page":"eadl4922","DOI":"10.1126\/scitranslmed.adl4922","article-title":"Complement is activated in patients with acute chest syndrome caused by sickle cell disease and represents a therapeutic target","volume":"17","author":"Chonat","year":"2025","journal-title":"Sci Transl Med"},{"key":"2026022411371695300_bib6","first-page":"6","article-title":"Complement system part II: role in immunity","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"1","key":"2026022411371695300_bib7","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2026022411371695300_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.transci.2016.04.012","article-title":"The alternative pathway of complement and the thrombotic microangiopathies","volume":"54","author":"Teoh","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"2026022411371695300_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I \u2013 molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"7","key":"2026022411371695300_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in disease: a defence system turning offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2026022411371695300_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajh.25384","article-title":"Critical role of C5a in sickle cell disease","volume":"94","author":"Vercellotti","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2026022411371695300_bib12","doi-asserted-by":"crossref","first-page":"e96910","DOI":"10.1172\/jci.insight.96910","article-title":"Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles","volume":"3","author":"Merle","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"2026022411371695300_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica"},{"key":"2026022411371695300_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2022.06.018","article-title":"MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease","volume":"249","author":"Belcher","year":"2022","journal-title":"Transl Res"},{"issue":"2","key":"2026022411371695300_bib15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2026022411371695300_bib16","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1073\/pnas.1814797116","article-title":"P-selectin drives complement attack on endothelium during intravascular hemolysis in TLR-4\/heme-dependent manner","volume":"116","author":"Merle","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026022411371695300_bib17","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4049\/jimmunol.1900047","article-title":"Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood","volume":"203","author":"Thomas","year":"2019","journal-title":"J Immunol"},{"key":"2026022411371695300_bib18","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3389\/fimmu.2018.03008","article-title":"Heme drives susceptibility of glomerular endothelium to complement overactivation due to inefficient upregulation of heme oxygenase-1","volume":"9","author":"May","year":"2018","journal-title":"Front Immunol"},{"key":"2026022411371695300_bib19","doi-asserted-by":"crossref","first-page":"901876","DOI":"10.3389\/fimmu.2022.901876","article-title":"Heme interferes with complement factor I-dependent regulation by enhancing alternative pathway activation","volume":"13","author":"Gerogianni","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2026022411371695300_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molmed.2016.01.004","article-title":"Heme: modulator of plasma systems in hemolytic diseases","volume":"22","author":"Roumenina","year":"2016","journal-title":"Trends Mol Med"},{"issue":"3","key":"2026022411371695300_bib21","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/jcm11030630","article-title":"Plasma-derived hemopexin as a candidate therapeutic agent for acute vaso-occlusion in sickle cell disease: preclinical evidence","volume":"11","author":"Gentinetta","year":"2022","journal-title":"J Clin Med"},{"key":"2026022411371695300_bib22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.HS9.0000843960.95232.5f","article-title":"Properdin-blocking antibodies attenuate complement alternative pathway activation triggered by cell-free heme in sickle cell disease models abstract]","volume":"6","author":"Trovati Maciel","year":"2022","journal-title":"HemaSphere"},{"issue":"11","key":"2026022411371695300_bib23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"Mcgann","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"2026022411371695300_bib24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"25","key":"2026022411371695300_bib25","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"11","key":"2026022411371695300_bib26","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2026022411371695300_bib27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ekir.2016.08.015","article-title":"Complement activation induces neutrophil adhesion and neutrophil-platelet aggregate formation on vascular endothelial cells","volume":"2","author":"Riedl","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"6","key":"2026022411371695300_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/jth.14767","article-title":"Vascular endothelial cells evade complement-mediated membrane injury via Weibel-Palade body mobilization","volume":"18","author":"Riedl Khursigara","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026022411371695300_bib29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.hemonc.2021.08.002","article-title":"Changes in heme levels during acute vaso-occlusive crisis in sickle cell anemia","volume":"16","author":"Cardoso","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"2026022411371695300_bib30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/15353702231157920","article-title":"Assessment of total and unbound cell-free heme in plasma of patients with sickle cell disease","volume":"248","author":"Vissa","year":"2023","journal-title":"Exp Biol Med (Maywood)"},{"issue":"14","key":"2026022411371695300_bib31","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.analchem.0c00415","article-title":"Heme determination and quantification methods and their suitability for practical applications and everyday use","volume":"92","author":"Hopp","year":"2020","journal-title":"Anal Chem"},{"issue":"9","key":"2026022411371695300_bib32","doi-asserted-by":"crossref","first-page":"e70209","DOI":"10.1002\/hem3.70209","article-title":"Elevated serum heme oxygenase-1 in pediatric sickle cell disease: insights from the SickleGenAfrica network","volume":"9","author":"Sowa","year":"2025","journal-title":"Hemasphere"},{"issue":"24","key":"2026022411371695300_bib33","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.2024025850","article-title":"Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy","volume":"144","author":"Cole","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2026022411371695300_bib34","first-page":"57","article-title":"Plasma haemoglobin and complement activation in sickle cell disease","volume":"6","author":"DeCeulaer","year":"1981","journal-title":"J Clin Lab Immunol"},{"issue":"21","key":"2026022411371695300_bib35","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1182\/blood.V124.21.4890.4890","article-title":"Comparison of clinical outcomes between adult and pediatric patients (pts) with sickle cell disease (SCD): 3-year (y) follow-up in a prospective, longitudinal, noninterventional registry trial","volume":"124","author":"Heeney","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2026022411371695300_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2026022411371695300_bib37","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","volume":"102","author":"Gavriilaki","year":"2017","journal-title":"Haematologica"},{"issue":"7","key":"2026022411371695300_bib38","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1002\/hem3.135","article-title":"Prospective study of complement activation and thromboinflammation within sickle cell disease and its complications","volume":"8","author":"Varelas","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"2026022411371695300_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0090-1229(85)90139-4","article-title":"Increased activation of the alternative complement pathway in sickle cell disease","volume":"37","author":"Chudwin","year":"1985","journal-title":"Clin Immunol Immunopathol"},{"key":"2026022411371695300_bib40","doi-asserted-by":"crossref","first-page":"1007102","DOI":"10.3389\/fimmu.2022.1007102","article-title":"Pitfalls in complement analysis: a systematic literature review of assessing complement activation","volume":"13","author":"Brandwijk","year":"2022","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1168\/2503737\/blooda_adv-2025-016958-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1168\/2503737\/blooda_adv-2025-016958-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:37:28Z","timestamp":1771951048000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1168\/548295\/Comprehensive-analysis-of-complement-activation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016958","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,13]]}}}